#RESEARCH RESULT 1 - PERPLEXITY

# Performance Management Framework for Pharmaceutical Manufacturing: A Comprehensive Analysis of Industry Practices

This comprehensive research study examines the fundamental operational practices of performance management in pharmaceutical manufacturing and operations, revealing how leading companies systematically translate strategic objectives into measurable outcomes while maintaining regulatory compliance and operational excellence. The analysis identifies seven critical process steps that form the backbone of effective pharmaceutical performance management: goal breakdown and target setting, KPI definition and cascading, monitoring and performance dialogues, gap closure and continuous improvement, and three enabling processes covering data management, cultural transformation, and employee development. Research findings demonstrate that successful pharmaceutical manufacturers employ structured frameworks like Balanced Scorecard, OKRs, and Hoshin Kanri to ensure strategic alignment, while leveraging advanced technologies including MES systems, real-time analytics, and digital dashboards to enable data-driven decision making. The study reveals that companies achieving superior performance outcomes integrate these processes seamlessly across manufacturing, quality, supply chain, and engineering functions, with particular emphasis on automated deviation detection, systematic root cause analysis, and continuous improvement methodologies that drive both operational efficiency and regulatory compliance.

## Strategic Goal Translation and Target Setting

Pharmaceutical companies employ sophisticated methodologies to translate high-level strategic objectives into actionable, measurable targets that cascade throughout their manufacturing operations. The **Balanced Scorecard** framework has emerged as a particularly effective tool for pharmaceutical companies, providing a structured approach that integrates financial performance with customer satisfaction, internal processes, and learning and growth perspectives[^4]. This comprehensive view is essential in the pharmaceutical industry where companies must balance innovation with regulatory compliance, cost management, and market competition.

The goal deployment process typically begins with strategic planning workshops where senior leadership, including site management, department heads from manufacturing, quality, supply chain management, and engineering, collaborate to define organizational priorities[^4]. These sessions involve reviewing the company's strategic plan, site objectives, and budget constraints to establish realistic baselines for new targets. Companies commonly utilize **Hoshin Kanri** (policy deployment) as a systematic approach for communicating strategic goals throughout the organization and putting them into action[^5]. This methodology, which translates to "compass management," requires a strategic vision and clearly defined objectives written for long-term timeframes of one to five years.

### Goal Cascade and Framework Implementation

The implementation of goal cascading frameworks involves several granular tasks that ensure effective translation from strategic to operational levels. Manufacturing teams conduct structured goal deployment workshops where participants identify and map dependencies between departmental or functional targets[^1]. These workshops utilize established frameworks such as OKRs (Objectives and Key Results), which have proven particularly valuable in pharmaceutical settings for aligning company objectives with specific results while ensuring unified direction and increased accountability across departments[^7].

**OKR strategies** in pharmaceutical businesses provide a clear framework that bridges the gap between high-level objectives and on-the-ground execution[^7]. Given the complex nature of the pharmaceutical industry, from rigorous research and development to regulatory compliance and market dynamics, OKRs offer a structured approach to prioritize goals, measure progress, and ensure team synchronization. This alignment results in improved efficiency in drug development, quicker response to market demands, and consistent focus on patient-centric outcomes.

The documentation and communication of targets to relevant teams involves creating departmental scorecards and documented goals that serve as key outputs of the goal-setting process[^1]. Finance departments typically interface with this process to provide budget-related inputs and ensure cost targets align with overall financial objectives. Human Resources departments contribute by aligning individual performance objectives with organizational targets, ensuring that goal achievement is reflected in employee development and compensation frameworks.

## KPI Definition and Cascading Systems

The definition and cascading of Key Performance Indicators (KPIs) in pharmaceutical manufacturing requires a sophisticated approach that balances strategic relevance with operational practicality. Manufacturing operations must track multiple categories of KPIs to achieve the critical goal of "100% order fulfillment on time" or Right First Time (RFT) delivery[^8]. This comprehensive measurement approach addresses the increasing complexity of global pharmaceutical supply chains, which have grown from approximately 110 billion dollars in 2000 to roughly 630 billion dollars in 2019.

### KPI Framework Development and Standardization

Pharmaceutical companies implement **harmonized KPI frameworks** that ensure consistency across different operational levels, from site and department to production line and individual performance metrics[^1]. The process of selecting relevant KPIs involves analyzing specific goals and operational requirements, with particular attention to regulatory compliance and quality standards. Manufacturing execution systems (MES) play a crucial role in this process, as they track and trace materials throughout the production process while monitoring key quality parameters such as temperature, pressure, and pH levels[^10].

The definition of KPI calculation methodologies requires close collaboration between process owners, data owners, and IT departments to ensure reliable data sourcing[^1]. Companies establish KPI dictionaries that document calculation procedures, data sources, and reporting frequencies, creating a standardized reference for all stakeholders. This documentation process addresses common pain points including non-achievable targets, excessive numbers of KPIs, and lack of transparency in cascade processes.

**Quality control integration** represents a critical aspect of pharmaceutical KPI definition, as MES systems must monitor and record quality parameters throughout production processes[^10]. By collecting and analyzing this data in real-time, manufacturing teams can identify and address deviations from quality standards, ensuring products meet required specifications. This real-time monitoring capability enables proactive steering and strategic alignment at every operational level.

The cascading process involves ensuring KPIs are aligned across functions to avoid conflicts, particularly between manufacturing efficiency targets and quality compliance requirements[^1]. Finance departments contribute cost-related KPIs that must be balanced with operational performance metrics, while process improvement teams ensure that KPIs support continuous improvement initiatives rather than hindering innovation.

## Performance Monitoring and Dialogue Processes

Pharmaceutical manufacturers have developed sophisticated monitoring systems that enable real-time performance tracking and structured dialogue processes throughout their organizations. These systems address the critical need for automated deviation detection and proactive alerting mechanisms that support rapid response to performance gaps[^1]. The implementation of tiered performance review meetings creates a comprehensive communication framework that spans from daily shift huddles to monthly site reviews.

### Real-Time Monitoring and Automated Systems

The foundation of effective performance monitoring lies in **unified data and tools** that provide comparable, actionable insights across all organizational levels[^1]. Manufacturing execution systems serve as the backbone for data collection, integrating with enterprise resource planning (ERP) systems, laboratory information management systems (LIMS), and other software applications used in production processes[^10]. This integration ensures accurate and efficient data sharing across departments, streamlining operations and reducing error risks.

Digital dashboards and action-focused visualization tools have become standard practice for displaying KPI data in manufacturing environments[^1]. These systems enable shop floor operators and management teams to access real-time performance data through digital boards and dashboards that replace traditional manual tracking methods. The visualization of performance data supports immediate identification of deviations and facilitates rapid response to emerging issues.

**Automated deviation detection** capabilities represent a significant advancement in pharmaceutical manufacturing monitoring[^1]. These systems analyze performance patterns and trigger alerts when KPIs deviate from established targets or acceptable ranges. This automation addresses previous pain points related to manual KPI deviation detection and slow gap-closing processes that characterized traditional monitoring approaches.

### Structured Performance Dialogue Implementation

The implementation of structured performance dialogues follows a tiered approach that ensures consistent communication and accountability across all organizational levels[^1]. Daily shift huddles involve frontline operators and supervisors reviewing immediate performance metrics, identifying short-term issues, and assigning corrective actions. These meetings typically focus on safety, quality, delivery, and cost metrics that directly impact daily operations.

Weekly departmental reviews expand the scope to include departmental managers and cross-functional representatives who assess performance trends and coordinate resources for addressing systemic issues[^1]. These sessions involve reviewing performance against targets, conducting initial root cause assessments for significant deviations, and tracking progress on previously assigned action items. The outputs include updated performance boards, meeting minutes, and new action items with clear ownership and timelines.

Monthly site reviews represent the highest level of performance dialogue, involving site management, department heads, and continuous improvement teams[^1]. These comprehensive sessions analyze performance patterns across multiple departments, assess the effectiveness of improvement initiatives, and align operational performance with strategic objectives. The interface with continuous improvement teams ensures that performance gaps are systematically addressed through structured improvement processes.

## Gap Closure and Continuous Improvement Methodologies

Pharmaceutical manufacturers employ systematic approaches to analyze performance gaps and implement effective corrective and preventive actions that prevent recurrence of issues. **Root Cause Analysis (RCA)** serves as the foundation for gap closure activities, utilizing structured methodologies to identify fundamental causes of problems or deviations in manufacturing processes[^9]. This systematic approach is critical for maintaining product quality and ensuring patient safety within Good Manufacturing Practice (GMP) frameworks.

### Formal Root Cause Analysis Implementation

The implementation of formal RCA processes follows established methodologies including the 5 Whys, Ishikawa diagrams (fishbone analysis), and Failure Modes and Effects Analysis (FMEA)[^9]. These tools enable investigation teams to systematically explore all possible causes of problems while analyzing objective evidence from production records, equipment logs, and environmental monitoring data. The evidence-based analysis approach ensures RCA credibility and supports the development of effective corrective actions.

**RCA methodology selection** depends on the complexity and significance of the performance deviation, with pharmaceutical companies maintaining standardized procedures for each approach[^9]. The 5 Whys technique provides a straightforward method for addressing relatively simple issues, while FMEA offers comprehensive analysis capabilities for complex manufacturing processes. Companies typically train cross-functional teams in multiple RCA methodologies to ensure appropriate tool selection based on specific circumstances.

The systematic investigation process requires careful planning and structured execution, moving beyond ad hoc approaches to establish consistent problem-solving capabilities[^9]. Investigation teams examine production records, equipment logs, environmental monitoring data, and conduct interviews with staff involved in incidents. This comprehensive data collection approach ensures that all relevant factors are considered in the analysis process.

### Continuous Improvement Project Management

The development and prioritization of **Corrective and Preventive Actions (CAPAs)** follows structured processes that integrate with quality assurance systems and regulatory requirements[^1]. CAPA management systems track the implementation and effectiveness of improvement actions while maintaining documentation required for regulatory compliance. These systems interface with dedicated continuous improvement teams, quality assurance departments, engineering, and operational units.

**Kaizen events and Lean Six Sigma projects** represent common approaches for implementing improvement initiatives in pharmaceutical manufacturing[^15]. These methodologies focus on eliminating waste and non-value-added activities while enhancing customer satisfaction through systematic process optimization. Companies utilize these approaches to achieve just-in-time improvements, quality enhancements, inventory reduction, and optimization of teamwork and flexibility.

The tracking of implementation and effectiveness measurement involves project management software and CAPA systems that monitor progress against established timelines and success criteria[^1]. Regular effectiveness assessments ensure that implemented solutions achieve intended results and prevent recurrence of issues. Companies document savings and benefits from improvement projects, providing quantitative evidence of continuous improvement program value.

**Lessons learned sharing** and best practices documentation create organizational learning capabilities that extend improvement benefits across multiple sites and departments[^1]. Knowledge management systems capture successful improvement approaches and make them accessible to teams facing similar challenges. This systematic knowledge sharing accelerates problem resolution and prevents duplication of improvement efforts.

## Data Collection and Analysis Infrastructure

The establishment of unified, real-time data foundations represents a critical enabler for effective performance management in pharmaceutical manufacturing. Companies face significant challenges related to data fragmentation, with multiple systems including MES, LIMS, ERP, and manual logging systems generating performance-relevant information[^1]. The creation of a **single source of truth** requires systematic integration of these disparate data sources while ensuring data quality and integrity for reliable performance reporting.

### Data Integration and Quality Management

**Manufacturing Execution Systems (MES)** serve as central platforms for collecting production data and integrating with other enterprise systems[^10]. These systems track materials throughout production processes, monitor critical quality parameters, and provide real-time visibility into manufacturing operations. The integration capabilities of MES platforms enable seamless connection with ERP systems for resource planning and LIMS for laboratory data management.

Data quality assurance involves implementing standardized procedures for data collection, validation, and transformation processes[^1]. Companies establish data definitions and maintain consistency across different systems and departments to ensure reliable KPI calculations. This standardization addresses common pain points including manual entries, lack of real-time data, and inconsistent data resolution across different operational areas.

**ETL (Extract, Transform, Load) processes** enable aggregation and transformation of raw data from operational systems into formats suitable for KPI calculation and analysis[^1]. These automated processes reduce manual intervention and improve data accuracy while supporting real-time or near-real-time performance reporting. Companies utilize databases and basic BI (Business Intelligence) tools to store and analyze transformed data.

### Advanced Analytics and Reporting Systems

The implementation of **harmonized data models** creates standardized frameworks for data structure and relationships across different operational systems[^1]. These models enable automated KPI calculation and support advanced analytics tools that provide deeper insights into performance patterns and trends. Companies are increasingly investing in AI-supported analysis capabilities that identify performance improvement opportunities and predict potential issues.

Basic data analysis capabilities include trending analysis, variance analysis, and performance pattern recognition that support performance dialogues and decision-making processes[^1]. These analytical approaches help identify recurring issues, seasonal patterns, and operational anomalies that require attention from management teams. The outputs from basic analysis include datasets for KPI calculation and analytical reports that inform performance discussions.

**Real-time alerting systems** and smart alerting capabilities enable proactive response to performance deviations[^1]. These systems monitor key performance indicators continuously and trigger notifications when values exceed established thresholds or when concerning patterns emerge. The integration of alerting systems with communication platforms ensures that relevant stakeholders receive timely information about performance issues.

## Cultural Change Management and Performance Mindset Development

The transformation toward a data-driven, performance-oriented culture in pharmaceutical manufacturing requires systematic approaches that address both behavioral and organizational factors. Companies must overcome natural resistance to change while building data literacy and business acumen throughout their organizations[^1]. **Performance mindset cultivation** involves leadership behaviors, communication strategies, and recognition programs that reinforce the importance of data-driven decision making.

### Leadership Engagement and Communication Strategies

**Management support and behavioral transparency** represent critical success factors for cultural transformation initiatives[^1]. Leadership teams must demonstrate commitment to performance management through consistent participation in performance dialogues, visible use of data for decision making, and accountability for performance outcomes. This consistent management approach addresses common pain points including lack of ambitious performance mindset and insufficient management commitment.

Communication strategies focus on articulating the importance of performance management and data utilization throughout the organization[^1]. Companies develop comprehensive communication plans that explain how performance management initiatives support patient safety, regulatory compliance, and business sustainability. These communications address employee concerns about change while highlighting benefits for individual career development and organizational success.

**Gemba walks and visual management** techniques enable leadership teams to demonstrate commitment to performance improvement while engaging directly with frontline employees[^1]. These approaches involve regular visits to production areas where leaders observe processes, review performance boards, and engage in discussions about improvement opportunities. Visual management systems make performance data accessible and understandable at the shop floor level.

### Training and Development Programs

**Data literacy development** programs provide employees with essential skills for interpreting and utilizing performance data in their daily work[^1]. These training initiatives address varying levels of data savviness across the organization while building confidence in data-driven decision making. Companies typically implement tiered training approaches that provide basic data interpretation skills for all employees and advanced analytical capabilities for key roles.

Business acumen enhancement involves training programs that help employees understand how their individual performance contributions support broader organizational objectives[^1]. These programs explain connections between operational metrics and business outcomes, regulatory compliance requirements, and patient safety considerations. The training helps employees make informed decisions that balance multiple priorities and constraints.

**Recognition and reward systems** align with performance management objectives by celebrating contributions to improvement initiatives and data-driven achievements[^1]. Companies implement formal recognition programs that highlight successful improvement projects, innovative problem-solving approaches, and consistent achievement of performance targets. These programs reinforce desired behaviors while building momentum for continued cultural transformation.

The management of resistance to new performance management processes requires structured change management approaches that address concerns and provide support for adaptation[^1]. Companies utilize change readiness assessments to identify potential obstacles and develop targeted interventions that support successful adoption of new processes and tools.

## Employee Qualification and Development Systems

Pharmaceutical companies implement comprehensive training and development programs that build both technical capabilities and cultural alignment with performance management objectives. These programs address the complex skill requirements for modern pharmaceutical manufacturing, including understanding of KPIs, proficiency with digital tools, participation in performance dialogues, and root cause analysis capabilities[^1]. The **personalized training approaches** ensure that development activities match individual role requirements and existing competency levels.

### Competency-Based Training Framework

The identification of training needs related to performance management involves systematic assessment of role requirements and skill gaps across different organizational levels[^1]. Companies conduct competency assessments that evaluate employee understanding of performance metrics, ability to use dashboards and analytical tools, and proficiency in participating in structured performance discussions. These assessments inform the development of targeted training programs that address specific capability gaps.

**Digital application training** has become increasingly important as pharmaceutical manufacturers adopt advanced technologies for performance management[^1]. Training programs cover the use of MES systems, digital dashboards, analytical tools, and mobile applications that support real-time performance monitoring. Companies provide hands-on training opportunities that enable employees to practice using new technologies in controlled environments before deploying them in production settings.

Training material development involves creating comprehensive resources including user guides, video tutorials, standard operating procedures, and quick reference materials[^1]. Companies develop **Performance Management Playbooks** that provide step-by-step guidance for common performance management activities such as conducting performance dialogues, interpreting KPI trends, and participating in improvement initiatives.

### Continuous Development and Coaching

**On-the-job coaching** programs provide sustained support for employees as they develop performance management capabilities[^1]. Experienced supervisors and subject matter experts work with employees to reinforce training concepts while providing guidance for real-world application of performance management tools and techniques. This coaching approach addresses the gap between classroom learning and practical implementation.

Competency assessment and documentation processes ensure that employees demonstrate required capabilities before assuming full responsibility for performance management activities[^1]. Companies maintain training records that track individual progress and identify areas requiring additional development. These records support compliance requirements while providing data for optimizing training program effectiveness.

**Automated learning suggestions** and continuous development tracking systems utilize performance data to identify training opportunities and recommend development activities[^1]. These systems analyze individual performance patterns and suggest relevant training modules or coaching interventions that could improve effectiveness. The integration of learning management systems with performance management platforms enables data-driven approaches to employee development.

The interface between HR/Training departments, department managers, and Performance Management system owners ensures that training programs remain aligned with operational requirements and technology evolution[^1]. Regular reviews of training effectiveness and updates to curriculum content ensure that development programs continue to meet changing business needs and technology capabilities.

## Conclusion

This comprehensive analysis reveals that successful pharmaceutical performance management requires the systematic integration of strategic goal setting, comprehensive KPI frameworks, real-time monitoring systems, structured improvement processes, and robust enablers including data infrastructure, cultural transformation, and employee development. The research demonstrates that leading pharmaceutical manufacturers achieve superior operational outcomes by implementing standardized frameworks such as Balanced Scorecard, OKRs, and Hoshin Kanri while leveraging advanced technologies including MES systems, automated deviation detection, and real-time analytics platforms.

The critical success factors identified include leadership commitment to data-driven decision making, comprehensive integration across manufacturing, quality, supply chain, and engineering functions, and sustained investment in employee capability development. Companies that excel in performance management establish clear governance structures for goal cascading, maintain unified data foundations that enable automated KPI calculation, and implement tiered performance dialogue processes that ensure accountability at all organizational levels.

The evolution toward Industry 4.0 technologies presents significant opportunities for pharmaceutical manufacturers to enhance their performance management capabilities through artificial intelligence, predictive analytics, and advanced automation systems. However, the research emphasizes that technological advancement must be accompanied by cultural transformation and employee development to achieve sustainable performance improvements. Organizations that successfully balance technological innovation with human capability development position themselves to achieve operational excellence while maintaining regulatory compliance and ensuring patient safety in an increasingly complex global marketplace.


[^1]: paste.txt

[^2]: https://www.emerald.com/insight/content/doi/10.1108/TQM-04-2024-0160/full/html

[^3]: https://www.zs.com/insights/4-factors-pharma-global-field-deployment

[^4]: https://www.linkedin.com/pulse/balanced-scorecard-pharma-performance-kiran-kumar-y-v-5m4jc

[^5]: https://en.wikipedia.org/wiki/Hoshin_Kanri

[^6]: https://www.linkedin.com/pulse/allocation-sales-target-pharmaceuticals-rep-abu-zafor-iqbal-ahamed-fxxwc

[^7]: https://datalligence.ai/blogs/okr-strategies-in-pharma-business/

[^8]: https://www.griddynamics.com/blog/kpis-for-pharmaceutical-manufacturing-operations

[^9]: https://gmpinsiders.com/steps-on-how-to-perform-rca/

[^10]: https://www.idbs.com/knowledge-base/what-are-the-key-features-of-a-pharma-mes-system/

[^11]: https://link.springer.com/10.1007/s10845-021-01860-6

[^12]: https://www.pharmamanufacturing.com/quality-risk/qrm-process/article/11358291/pharma-pat-a-practical-structured-approach-to-deploying-process-analytical-technology-in-a-manufacturing-environment-pharmaceutical-manufacturing

[^13]: https://ojs.journalsdg.org/jlss/article/view/2439

[^14]: https://shoplogix.com/seven-production-goals-manufacturers-should-reach/

[^15]: https://www.matec-conferences.org/10.1051/matecconf/202440110004

[^16]: https://www.isixsigma.com/methodology/goal-deployment/

[^17]: https://www.mdpi.com/2504-4494/8/5/215

[^18]: https://www.mckinsey.com/industries/life-sciences/our-insights/four-ways-to-make-sure-your-pharma-manufacturing-strategy-delivers-value

[^19]: https://onlinelibrary.wiley.com/doi/10.1002/solr.202300102

[^20]: https://www.openaccessgovernment.org/article/process-intensification-a-game-changer-for-the-pharma-market/188486/

[^21]: https://www.emerald.com/insight/content/doi/10.1108/JMTM-08-2020-0313/full/html

[^22]: https://link.springer.com/10.1007/978-3-030-59975-1_9

[^23]: http://link.springer.com/10.1007/s13198-016-0478-3

[^24]: https://www.semanticscholar.org/paper/0020ac4d3411cf0e966e8550b688d527d6c827eb

[^25]: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q11-development-and-manufacture-drug-substances-chemical-entities-and-biotechnologicalbiological-entities_en.pdf

[^26]: https://www.semanticscholar.org/paper/1a77e31bf26fcb9020b2a054fe53295ef860ec24

[^27]: https://www.semanticscholar.org/paper/84aec4e88b6d757df650e9b052fe7eee49b85f66

[^28]: https://www.semanticscholar.org/paper/e54c52b10d291de055723f3effab8ece0160f7ff

[^29]: https://repositorio.iscte-iul.pt/bitstream/10071/1148/1/TESE RMGJ.pdf

[^30]: https://support.sas.com/resources/papers/proceedings-archive/SEUGI2003/Cron_introductionofabsc.pdf

[^31]: https://www.ost.ch/fileadmin/dateiliste/3_forschung_dienstleistung/zentren_fachstellen/wtt/pr_berichte/2006/ppj3_altana.pdf

[^32]: https://repositorio-iul.iscte.pt/bitstream/10071/13969/1/The Balanced Scorecard in a Pharmaceutical Company.pdf

[^33]: https://okrinternational.com/okr-examples-biotechnology-pharmaceuticals/

[^34]: https://www.semanticscholar.org/paper/5a163d8887ce19dc48884588d22143e0a2fe6769

[^35]: https://www.emerald.com/insight/content/doi/10.1108/17410380710763895/full/html

[^36]: https://www.amazon.de/Hoshin-Kanri-Lean-Enterprise-Capabilities/dp/1138438766

[^37]: https://www.cascade.app/templates/pharmaceutical-manufacturing-strategy-template

[^38]: https://explore.darwinbox.com/lp/resources/ebook/the-ultimate-guide-to-goal-cascading

[^39]: https://www.mesh.ai/blogs/top-down-goal-cascades-cascade-well-on-paper-but-not-in-reality

[^40]: https://www.cascade.app/blog/manufacturing-strategy

[^41]: https://insightsoftware.com/blog/15-best-pharma-kpis-and-metric-examples/

[^42]: https://www.nature.com/articles/s41586-022-04422-9

[^43]: https://www.nature.com/articles/s41587-023-01725-8

[^44]: https://www.pharmexec.com/view/balanced-scorecard-rd

[^45]: https://ieeexplore.ieee.org/document/10956513/

[^46]: https://ejournal.upnvj.ac.id/vemar/article/view/8710

[^47]: https://www.nepjol.info/index.php/amcjd/article/view/69127

[^48]: https://www.sciendo.com/article/10.2478/picbe-2024-0172

[^49]: https://www.mdpi.com/1999-4923/13/9/1371

[^50]: http://www.asianonlinejournals.com/index.php/AJSSMS/article/view/1836

[^51]: https://www.semanticscholar.org/paper/cc49a6b8728238ddfae59ebfe0b840bf03de2931

[^52]: https://www.kontor-gruppe.de/hoshin-kanri.html

[^53]: https://www.drescher-consulting.de/aktuelle-themen/strategieumsetzung-mit-hoshin-kanri/

[^54]: https://journal.untar.ac.id/index.php/JMTI/article/view/32012

[^55]: https://www.emerald.com/insight/content/doi/10.1108/TQM-07-2022-0216/full/html

[^56]: https://www.emerald.com/insight/content/doi/10.1108/MRR-04-2018-0178/full/html

[^57]: https://www.emerald.com/insight/content/doi/10.1108/MD-03-2016-0148/full/html

[^58]: https://ieeexplore.ieee.org/document/9672882/

[^59]: https://www.emerald.com/insight/content/doi/10.1108/TQM-06-2018-0076/full/html

[^60]: https://www.emerald.com/insight/content/doi/10.1108/TQM-03-2014-0035/full/html

[^61]: https://www.lean-partners.de/beratung/toyota-kata/hoshin-kanri/

[^62]: https://www.sesa-systems.de/hoshin

[^63]: https://refa.de/service/refa-lexikon/hoshin-kanri

[^64]: https://shoplogix.com/hoshin-kanri-why-its-important-for-manufacturers/

[^65]: https://www.leanproduction.com/hoshin-kanri/

[^66]: https://pmc.ncbi.nlm.nih.gov/articles/PMC10264874/

[^67]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7719360/

[^68]: https://pmc.ncbi.nlm.nih.gov/articles/PMC4759219/

[^69]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11619126/

[^70]: https://pmc.ncbi.nlm.nih.gov/articles/PMC8466472/

[^71]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7150984/

[^72]: https://pmc.ncbi.nlm.nih.gov/articles/PMC5866991/

[^73]: https://entomo.co/blog/using-goal-cascading-in-the-pharmaceuticals-industry-a-step-by-step-guide/

[^74]: https://www.orbussoftware.com/resources/video-library/video/cobit-5-goals-cascade

[^75]: https://pharmuni.com/2024/10/30/strategic-planning-in-pharmaceutical-production/

[^76]: https://cbsteam.com/connecting-the-dots-5-practical-strategies-for-cascading-your-strategic-vision-throughout-the-organization/

[^77]: https://tbmcg.com/resources/blog/hoshin-kanri-case-study-turning-strategy-into-reality/

[^78]: https://pmc.ncbi.nlm.nih.gov/articles/PMC9425710/

[^79]: https://pmc.ncbi.nlm.nih.gov/articles/PMC6604032/

[^80]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11344148/

[^81]: http://arxiv.org/pdf/2502.09527.pdf

[^82]: https://pmc.ncbi.nlm.nih.gov/articles/PMC8743089/

[^83]: https://ispe.org/pharmaceutical-engineering/ispeak/strategic-planning-measurable-outcomes-pharmaceutical

[^84]: https://www.pharmaceutical-technology.com/projects/cascade-chemistrys-manufacturing-facility-expansion-eugene/

[^85]: https://www.alliedreliability.com/blog/the-balanced-scorecard

[^86]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11350267/

[^87]: https://pmc.ncbi.nlm.nih.gov/articles/PMC11107368/

[^88]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7022419/

[^89]: https://pmc.ncbi.nlm.nih.gov/articles/PMC6812013/

[^90]: https://www.pharmasalmanac.com/articles/how-can-pharma-manufacturing-align-with-green-initiatives-while-maintaining-efficiency-and-compliance

[^91]: https://www.wiley-vch.de/de/fachgebiete/naturwissenschaften/continuous-manufacturing-of-pharmaceuticals-978-1-119-00132-4

[^92]: https://www.mckinsey.com/industries/life-sciences/our-insights/how-sterile-pharma-manufacturers-can-grow-capacity-without-capital-investment

[^93]: https://www.mlean.com/blog/what-is-hoshin-kanri/

[^94]: https://ieeexplore.ieee.org/document/10246680/

[^95]: https://www.mdpi.com/2071-1050/14/17/11004

[^96]: https://www.frontiersin.org/articles/10.3389/frtra.2023.1238535/full

[^97]: https://www.spiedigitallibrary.org/conference-proceedings-of-spie/12919/3011057/Digital-device-modeling-based-on-software-definition/10.1117/12.3011057.full

[^98]: https://dspace.tul.cz/server/api/core/bitstreams/bc2d2a70-08b6-4e39-bbbf-833be81634dc/content?authentication-token=eyJhbGciOiJIUzI1NiJ9.eyJlaWQiOiI5YjAwMzA5NC1kNzc1LTQwMWEtOGQ5YS05ZTdhN2QyNTEzZWYiLCJzZyI6W10sImF1dGhlbnRpY2F0aW9uTWV0aG9kIjoic2hpYmJvbGV0aCIsImV4cCI6MTcyNTYxMzIzNX0.oo9dyfV71eJCECABB4_2TkUfWtb5fWTFtGBEI-HsfrI

[^99]: https://www.tandfonline.com/doi/full/10.1080/17517575.2019.1701715

[^100]: https://openaccess.cms-conferences.org/publications/book/978-1-958651-12-4/article/978-1-958651-12-4_8

[^101]: https://www.mdpi.com/2071-1050/14/5/2602

[^102]: http://acta.uni-obuda.hu/Gaspar_Thalmeiner_Barta_Zeman_122.pdf

[^103]: https://www.mdpi.com/2076-3417/15/4/2013

[^104]: https://simplerqms.com/quality-kpis-pharmaceutical/

[^105]: https://scw.ai/blog/manufacturing-kpis/

[^106]: https://www.optiproerp.com/blog/important-kpis-for-manufacturing-production/

[^107]: https://www.processindustryforum.com/article/process-control-and-monitoring-for-the-pharmaceutical-industry

[^108]: https://insigniam.com/three-cultural-changes-that-create-pharma-blockbusters/

[^109]: https://www.facilityos.com/blog/what-pharma-facility-metrics-kpis-should-you-be-tracking

[^110]: https://ieeexplore.ieee.org/document/10333441/

[^111]: https://scindeks.ceon.rs/Article.aspx?artid=2490-33292404489A

[^112]: https://www.pharmjournal.ru/jour/article/view/1663

[^113]: https://medwinpublishers.com/OAJPR/current-status-and-challenges-of-serialization-in-pharma-industry.pdf

[^114]: https://onlinelibrary.wiley.com/doi/10.1002/nme.6617

[^115]: https://www.mdpi.com/1424-8220/19/24/5370

[^116]: https://ieeexplore.ieee.org/document/10977407/

#RESEARCH RESULT 2 - ANTHROPIC